PEA

Suspected endocannabinoid.

OEA

Suspected endocannabinoid.

2AGE/Noladin

Suspected cannabinoid that binds to several cannabinoid receptors.

Anandamide

Anandamide was the first identified endocannabinoid, named after the Sanskrit 'ananda' for inner bliss. Anandamide is produced from lipids in cellular membranes throughout the body.

Stroke

A stroke is marked by reduced blood flow to the brain. This reduction can be due to a blocked blood vessle (ischaemia) or a ruptured blood vessle (aneurism). Either way, as a result (part of) the brain is deprived of oxygen and nutrients which in turn causes neuronal degradation and cognitive decline.

Parkinson's

Parkinson's Disease is a degenerative disorder of the nervous system marked by accelerated degeneration of dopamine-producing neurons in the Substantia Nigra in the brain.

Typical symptoms of Parkinson's Disease , such as (intentional) tremor, rigidity and slowness of movement are mostly ascribed to degenerating Substantia Nigra neurons.

Pain

Pain is a very good target for therapeutic cannabinoids. Many endocannabinoids, plant cannabinoids and cannabinoid receptors have been linked to pain management or analgesia.

Huntington's

Huntington's disease is a genetic neurodegenerative disorder, marked by preferential degeneration of neurons in the basal ganglia (caudate and putamen) and accompanied by motor deficits, cognitive impairment and psychiatric symptoms. There is considerable evidence for the involvement of the endocannabinoid system in Huntington's but clinical trials so far have been inconclusive.

Eczema

Eczema or dermatitis is a (chronic) inflammation of the skin. Eczema is marked by itchy skin and crusty skin lesions. It is not known what exactly causes eczema but an over-active immune system may at least be part of the cause. Therefore, a faulty endocannabinoid system may cause eczema offering potential for cannabinoid-based therapy.

Cystitis

Cystitis is an infection of the urinary tract.